Now Available: A Liquid Biopsy powered by Multiplexed ICE COLD-PCR!
Enabling Precision Treatment for Oncology Patients
Multiplexed ICE COLD-PCR (MX-ICP) analyzes circulating tumor DNA in the blood and can detect cancer DNA mutations down to 0.01%. This level of sensitivity can guide and monitor cancer treatment decisions for patients with Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), and Melanoma. MX-ICP selectively amplifies cancer mutant DNA preferentially over wild-type (normal DNA) providing a 100 to 500-fold increase in sensitivity compared to other testing methods. The genes we chose to offer MX-ICP testing for are suggested by cancer guidelines or treatment options are in clinical trials. This approach helps clinicians to select precision treatments that may improve patient outcomes.
|MX-ICP NSCLC Analysis||NSCLC||Multiplexed ICE COLD-PCR (MX-ICP) amplification and sequencing of EGFR exons 18, 19, 20, and 21, KRAS exons 2 and 3, BRAF exon 15, PIK3CA exons 9 and 20 to determine effective treatment options for Non-Small Cell Lung Cancer (NSCLC) patients.||Sensitivity or resistance to EGFR-TKI therapy, sensitivity to BRAF & PI3K inhibitors||7 - 10 business days|
|MX-ICP EGFR Analysis||NSCLC||Multiplexed ICE COLD-PCR (MX-ICP) amplification and sequencing of EGFR exons 18, 19, 20, and 21 to determine Non-Small Cell Lung Cancer (NSCLC) tumor sensitivity or resistance to EGFR-tyrosine kinase inhibitors (TKI).||Sensitivity or resistance to EGFR-TKI therapy||7 - 10 business days|
|MX-ICP RAS Analysis||CRC||Multiplexed ICE COLD-PCR (MX-ICP) amplification and sequencing of NRAS and KRAS exons 2, 3, and 4 to determine if the CRC tumor has reduced sensitivity to Anti-EGFR Antibody therapy.||Reduced sensitivity to Anti-EGFR Antibodies||7 - 10 business days|
|MX-ICP CRC Analysis||CRC||Multiplexed ICE COLD-PCR (MX-ICP) amplification and sequencing of EGFR exon 12 (S492R), BRAF exon 15, KRAS and NRAS exons 2, 3, and 4, PIK3CA exons 9 and 20 to determine effective treatment options for individuals with CRC.||Determine likely response to treatment options dependent on the gene mutation||7 – 10 business days|
|MX-ICP Melanoma Analysis||Melanoma||Multiplexed ICE COLD-PCR (MX-ICP) amplification and sequencing of BRAF exon 15 and NRAS exons 2 and 3 to detect mutations to help guide treatment decisions.||Determine likely response to treatment options dependent on the gene mutation||7 – 10 business days|
|MX-ICP EGFR Exon 20 (T790M) Analysis||NSCLC||Multiplexed ICE COLD-PCR amplification and sequencing of EGFR exon 20 (T790M) to detect if resistance has developed to EGFR-TKI therapy.||Resistance to EGFR-TKI treatment||7 - 10 business days|
|MX-ICP EGFR Exon 12 (S492R) Analysis||CRC||Multiplexed ICE COLD-PCR amplification and sequencing of EGFR exon 12 (S492R) to detect resistance to cetuximab.||Resistance to cetuximab||7 - 10 business days|
|MX-ICP PIK3CA Analysis||NSCLC/CRC||Multiplexed ICE COLD-PCR (MX-ICP) amplification and sequencing of PIK3CA to determine treatment options for cancers with this mutation.||Increased sensitivity to PI3K inhibitors||7 - 10 business days|
Shipping requirements: Room temperature
MX-ICP Preferentially Enriches Mutants in Cancer Cell DNA
The challenge with liquid biopsies is that relatively low levels of mutant cancer cells are circulating in blood. In addition, these cells are difficult to segregate from large amounts of normal cells. Multiplexed ICE COLD-PCR (Improved and Complete Enrichment CO-amplification at Lower Denaturation temperature) technology preferentially enriches mutant DNA sequences in an excess of wild-type (normal) DNA through selective amplification of the mutant DNA. The result is up to a 500-fold increase in sensitivity in identifying mutations with precise sequence alteration detection rates – down to 0.01%.*
*The concentration of mutant DNA in the total DNA sample
Amplified Sensitivity for Mutation Detection Down to 0.01%
MX-ICP Detects Mutations Accurately and Simply to Improve Patient Outcomes
The MX-ICP result reports are designed to highlight the most clinical relevant information presented in a concise manner. If you have questions pertaining to the result report, our Geneticists and Genetic Counselors are standing-by to guide you through the results.
Ultra-High Sensitivity MX-ICP Oncology Testing
Improved Mutation Detection to Enable Precision Treatment Decisions is at your finger tips. To give MX-ICP a try or for more information, please select the service you would like.
- Prabhakar, Charles. Epidermal growth factor receptor in non-small cell lung cancer. Transl Lung Cancer Res 2015; 4(2):110-118.
- Niederst, M., et al. C797S promotes resistance to third generation EGFR inhibitors. Clinc Cancer Res. May 11, 2015; DOI: 10. 1158/1078-0432.
- NCCN NSCLC Clinical Guidelines. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
- Price, TJ., et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomized, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014 May; 15(6):569-79.
- Leighl, N.B., et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Society for the Study of Lung Cancer/Association of Molecular Pathologists Guidelines. J Clin Oncol 32, No. 32, 3673-3679. November 10, 2014.